TABLE 5.
Truth | Observed data | |||
---|---|---|---|---|
Paroxetine use versus nonusers | Drug P1 | Drug P0 | Drug P1 | Drug P0 |
Y = 1 | 150 | 9900 | 217 | 9833 |
Y = 0 | 850 | 89 100 | 1450 | 88 500 |
Total | 1000 | 99 000 | 1667 | 98 333 |
Risk | 0.15 | 0.10 | 0.13 | 0.10 |
RR | 1.5 | 1.4 | ||
Escitalopram versus nonusers | Drug E1 | Drug E0 | Drug E1 | Drug E0 |
Y = 1 | 75 | 9950 | 87.5 | 9937.5 |
Y = 0 | 425 | 89 550 | 537.5 | 89437.5 |
Total | 500 | 99 500 | 625 | 99 375 |
Risk | 0.15 | 0.10 | 0.14 | 0.10 |
RR | 1.5 | 1.8 | ||
Escitalopram versus paroxetine | Drug P1 | Drug E1 | Drug P1 | Drug E1 |
Y = 1 | 150 | 75 | 217 | 87.5 |
Y = 0 | 850 | 425 | 145 | 537.5 |
Total | 1000 | 500 | 1667 | 625 |
Risk | 0.15 | 0.15 | 0.13 | 0.14 |
RRE−P | 1.0 | 1.08 |
Note: Values used: baseline risk: 0.1; RR: paroxetine 1.5, escitalopram 1.5; exposure prevalence: paroxetine 0.01, escitalopram 0.005; data capture: paroxetine 1.0, escitalopram 1.0; adherence: paroxetine 0.6, escitalopram 0.8.
Abbreviations: P1: exposed to paroxetine; E1 exposed to escitalopram; P0 and E0 nonexposed to paroxetine or escitalopram; Y = outcome.